ClinicalTrials.Veeva

Menu

Side Effects of Antibiotics in Bone and Joint Infections (PROSEAB)

R

Regional University Hospital Center (CHRU)

Status

Enrolling

Conditions

Joint Infection
Bone Infection

Study type

Observational

Funder types

Other

Identifiers

NCT05927311
DR230121-PROSEAB

Details and patient eligibility

About

Treatment for bone and joint infection (BJI) is not standardized, which allows a wide range of antibiotic therapy to potentially be given, most often in high doses over long periods of time. Patients are regularly confronted with the adverse effects of these antibiotics, which can lead to loss of adherence and treatment failure. The frequency, severity and impact on quality of life of the adverse effects of long-term antibiotics will be studied in a cohort followed for one year.

Full description

Treatment for bone and joint infection is not standardized, which allows a wide range of antibiotic therapy to potentially be given, most often in high doses over long periods of time. Patients are regularly confronted with the adverse effects of these antibiotics, which can lead to loss of adherence and treatment failure. Although patients with BJI receive regular follow-up, the impact of adverse events during treatments lasting more than a month is still poorly developed in the literature.

The frequency, severity and impact on quality of life of the adverse effects of long-term antibiotics will be studied in a cohort followed for one year.

The investigators believe that this study will improve the management of osteoarticular infections through a better understanding of the adverse effects associated with prolonged, high-dose antibiotic therapy, and encourage more multidisciplinary follow-up.

Enrollment

300 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient over 18 years of age
  • Microbiologically proven osteoarticular infection with or without material, requiring antibiotic therapy (single or multiple) of 6 weeks or more
  • Oral antibiotic therapy (minimum 4 weeks)

Exclusion criteria

  • Opposition to data processing
  • Patient under guardianship or trusteeship

Trial contacts and locations

1

Loading...

Central trial contact

Anne-Elisabeth ROYERE; Marion LACASSE

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems